Explore the latest in lung cancer, including advances in understanding epidemiology, risk factors, treatment biomarkers, and management.
This secondary analysis of tumor specimens collected for the LUX-Lung 8 randomized clinical trial assesses whether ERBB gene mutations of family members were associated with outcomes among patients with lung squamous cell carcinoma randomized to treatment with afatinib or erlotinib.
This case series describes 90-day mortality of patients who required tracheal, bronchial, or carinal reconstruction using stented aortic allografts supported by muscle flaps for treatment of inoperable airway disease including lung cancer, tracheal stenosis, or tracheomalacia.
This study evaluates the duration of response for crizotinib vs chemotherapy for patients with ALK-positive lung cancer using data from the PROFILE-1014 randomized clinical trial.
A middle-aged woman with non–small cell lung cancer presents with peripheral visual field loss in her left eye and a 4-mm metastatic lesion in her right temporal lobe. What would you do next?
This analysis of data from a single-arm clinical trial investigates whether stereotactic body radiation therapy delivered on an outpatient basis for patients with operable early-stage lung cancer is associated with primary tumor control, survival, adverse events, and the need for surgical resection.
This study evaluates 5-year data from the NRG Oncology RTOG 0236 trial on the effects of sterotactic body radiation therapy in patients with inoperable stage I non–small cell lung cancer.
This cost-effectiveness analysis of data from the FLAURA randomized clinical trial evaluates the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year of osimertinib as a first-line treatment for patients with EGFR-mutated advanced non–small cell lung cancer in the United States and Brazil.
This cohort study assesses the speed with which inhibitors of programmed cell death 1 protein reached eligible patients in practice and compares the ages of patients treated in clinical practice with the ages of those treated in pivotal clinical trials.
This Surgical Innovation describes sentinal lymph node mapping with near-infrared imaging to target the first tumor-draining lymph node for sampling and for in-depth pathologic analysis in non–small cell lung cancer.
This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer.
In this study, Global Burden of Disease investigators characterize trends in mortality, life expectancy, and prevalence associated with most common diseases and disease and mortality risk factors in the United States between 1990 and 2016.
This single-institution cohort study investigates whether clinicians routinely document the pretest probability of malignancy in patients with high-risk indeterminate pulmonary nodules and compares these estimates with those generated by the Mayo Clinic Model.
This Insights characterizes recent advances and describes a framework for the treatment of advanced non–small cell lung cancer.
This study examines how a high false-positive rate in lung cancer screening influences the harm-to-benefit ratio for higher- vs lower-risk patients.
This medical record review evaluates the relation of immune-related adverse events to nivolumab efficacy in non–small-cell lung cancer.
This cohort study investigates whether the pretreatment derived neutrophils/(leukocytes minus neutrophils) ratio and lactate dehydrogenase level are associated with resistance to immunotherapy in patients with advanced non–small cell lung cancer.
This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.
Customize your JAMA Network experience by selecting one or more topics from the list below.